- Potential mechanism for ocular toxicity in ADC formulations
- Mechanism of Action of ADCs
- Mechanism of ocular toxicity
- Pharmacokinetics and pharmacovigilance
- Efficacy of belantamab mafodotin in relapsed/refractory multiple myeloma
- Ocular toxicity from other investigational ADC therapies
- Safety data for belantamab mafodotin
- Safety data from DREAMM trials of belantamab mafodotin
- DREAMM-2 trial ocular substudy
- Recommended monitoring schedule
- Case challenge: Monitoring for a patient scheduled to receive ADC for relapsed/refractory multiple myeloma
- Risk Evaluation Management Strategy
- Panel discussion: communication between ophthalmology and oncology
- Recommendations for management of belantamab mafodotin–related corneal events
- Dose modifications and delays
- Grade 1 keratopathy with no changes in visual acuity
- Grade 2 keratopathy with ≤ 3 lines of decreased vision from baseline
- Grade 3/4 keratopathy with > 3 lines of decreased vision from baseline
- Severe reduction in visual acuity from baseline or corneal ulcer
- Case challenge: Managing low-grade toxicity from belantamab mafodotin
- Case challenge: Managing high-grade toxicity from belantamab mafodotin
- Panel discussion: Effective communication strategies between ophthalmology and oncology
- Closing Remarks and Learner Q&A
Date / Time
Anthony Perissinotti, PharmD, BCOP
Hematology Clinical Pharmacist Specialist
Clinical Team Leader, Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan, Michigan Medicine
Roger Cancer Center
Ann Arbor, Michigan
The primary purpose of this program is to arm ophthalmologists and optometrists with the latest data informing the monitoring and management of ocular toxicity from antibody–drug conjugates and providing multidisciplinary expert guidance in working together with the oncology/hematology care team to optimize clinical outcomes in patients with cancer who are receiving these therapies.
The goal of this program is to improve the knowledge and competence of learners in the mitigation and management of ocular toxicity for patients with cancer who are receiving antibody–drug conjugates.
This educational program is intended for ophthalmologists, optometrists, medical oncologists, and other clinicians who provide care for patients receiving antibody–drug conjugates for the treatment of cancer.
Upon completion of this activity, participants should be able to:
- Apply the available data and expert recommendations to optimally monitor for ocular toxicity in patients with cancer who are receiving antibody–drug conjugates
- Plan appropriate therapeutic interventions with treating hematologists and oncologists in patients experiencing ocular toxicities from antibody–drug conjugate therapy to maximize clinical outcomes from anticancer therapy and mitigate worsening keratopathy
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.